Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Josef S SmolenStefan SiebertTatiana V KorotaevaCarlo Francesco SelmiPaul BergmansElisa GremeseBeatriz Joven-IbáñezGkikas KatsifisWim NoëlMichael T NurmohamedPascal RichettePetros P SfikakisKurt de VlamElke TheanderLaure GossecPublished in: Annals of the rheumatic diseases (2021)
Treatment targets were reached similarly after 6 months of treatment with ustekinumab and TNFi.